File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide

TitleCombined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide
Authors
Au, WYChim, CSLie, AKWLiang, RKwong, YL
KeywordsAll-trans retinoic acid
Arsenic trioxide
Relapsed APL
Issue Date2002
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJH
Citation
British Journal Of Haematology, 2002, v. 117 n. 1, p. 130-132 How to Cite?
DOI: http://dx.doi.org/10.1046/j.1365-2141.2002.03409.x
AbstractThe optimal treatment of acute promyelocytic leukaemia (APL) recurring from relapses successfully treated using arsenic trioxide (As2O3) is undefined. Three APL patients relapsing from As2O3-induced remission were studied. Re-treatment with As2O3 failed in one patient in third relapse, and resulted in morphological but not molecular remission in another patient. Combination therapy with As2O3 and all-trans retinoic acid (ATRA), however, resulted in morphological and molecular remission in all three cases, with a follow-up time ranging from 6 to 16 months. Our results suggest a synergistic therapeutic effect between As2O3 and ATRA in APL in advanced relapse.
Persistent Identifierhttp://hdl.handle.net/10722/162595
ISSN
0007-1048
2023 Impact Factor: 5.1
2023 SCImago Journal Rankings: 1.574
ISI Accession Number ID
WOS:000175436000018
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_US
dc.contributor.authorChim, CSen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:21:32Z-
dc.date.available2012-09-05T05:21:32Z-
dc.date.issued2002en_US
dc.identifier.citationBritish Journal Of Haematology, 2002, v. 117 n. 1, p. 130-132en_US
dc.identifier.issn0007-1048en_US
dc.identifier.urihttp://hdl.handle.net/10722/162595-
dc.description.abstractThe optimal treatment of acute promyelocytic leukaemia (APL) recurring from relapses successfully treated using arsenic trioxide (As2O3) is undefined. Three APL patients relapsing from As2O3-induced remission were studied. Re-treatment with As2O3 failed in one patient in third relapse, and resulted in morphological but not molecular remission in another patient. Combination therapy with As2O3 and all-trans retinoic acid (ATRA), however, resulted in morphological and molecular remission in all three cases, with a follow-up time ranging from 6 to 16 months. Our results suggest a synergistic therapeutic effect between As2O3 and ATRA in APL in advanced relapse.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJHen_US
dc.relation.ispartofBritish Journal of Haematologyen_US
dc.rightsBritish Journal of Haematology. Copyright © Blackwell Publishing Ltd.-
dc.subjectAll-trans retinoic acid-
dc.subjectArsenic trioxide-
dc.subjectRelapsed APL-
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshArsenicals - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia, Promyelocytic, Acute - Drug Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshOxides - Administration & Dosageen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshTretinoin - Administration & Dosageen_US
dc.titleCombined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxideen_US
dc.typeArticleen_US
dc.identifier.emailChim, CS:jcschim@hku.hken_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityChim, CS=rp00408en_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1046/j.1365-2141.2002.03409.xen_US
dc.identifier.pmid11918543-
dc.identifier.scopuseid_2-s2.0-0036223312en_US
dc.identifier.hkuros77789-
dc.identifier.hkuros67016-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036223312&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume117en_US
dc.identifier.issue1en_US
dc.identifier.spage130en_US
dc.identifier.epage132en_US
dc.identifier.isiWOS:000175436000018-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridChim, CS=7004597253en_US
dc.identifier.scopusauthoridLie, AKW=24284842400en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.issnl0007-1048-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats